Considering that B cells in humans reportedly require BAFF for survival it is reasonable to assume that blockade of BAFF in patients would sensitize CLL cells to treatment-induced cell death [52,53]. Here, TNFSF13B is linked to B-cell chronic lymphocytic leukemia.